Literature DB >> 27058207

Extent of resection of peritumoral diffusion tensor imaging-detected abnormality as a predictor of survival in adult glioblastoma patients.

Jiun-Lin Yan1,2,3,4, Anouk van der Hoorn1,5,6, Timothy J Larkin1, Natalie R Boonzaier1, Tomasz Matys5, Stephen J Price1.   

Abstract

OBJECTIVE Diffusion tensor imaging (DTI) has been shown to detect tumor invasion in glioblastoma patients and has been applied in surgical planning. However, the clinical value of the extent of resection based on DTI is unclear. Therefore, the correlation between the extent of resection of DTI abnormalities and patients' outcome was retrospectively reviewed. METHODS A review was conducted of 31 patients with newly diagnosed supratentorial glioblastoma who underwent standard 5-aminolevulinic acid-aided surgery with the aim of maximal resection of the enhancing tumor component. All patients underwent presurgical MRI, including volumetric postcontrast T1-weighted imaging, DTI, and FLAIR. Postsurgical anatomical MR images were obtained within 72 hours of resection. The diffusion tensor was split into an isotropic (p) and anisotropic (q) component. The extent of resection was measured for the abnormal area on the p, q, FLAIR, and postcontrast T1-weighted images. Data were analyzed in relation to patients' outcome using univariate and multivariate Cox regression models controlling for possible confounding factors including age, O6-methylguanine-DNA-methyltrans-ferase methylation status, and isocitrate dehydrogenase-1 mutation. RESULTS Complete resection of the enhanced tumor shown on the postcontrast T1-weighted images was achieved in 24 of 31 patients (77%). The mean extent of resection of the abnormal p, q, and FLAIR areas was 57%, 83%, and 59%, respectively. Increased resection of the abnormal p and q areas correlated positively with progression-free survival (p = 0.009 and p = 0.006, respectively). Additionally, a larger, residual, abnormal q volume predicted significantly shorter time to progression (p = 0.008). More extensive resection of the abnormal q and contrast-enhanced area improved overall survival (p = 0.041 and 0.050, respectively). CONCLUSIONS Longer progression-free survival and overall survival were seen in glioblastoma patients in whom more DTI-documented abnormality was resected, which was previously shown to represent infiltrative tumor. This highlights the potential usefulness and the importance of an extended resection based on DTI-derived maps.

Entities:  

Keywords:  5-Ala = 5-aminolevulinic acid; DT = diffusion tensor; DTI = diffusion tensor imaging; EOR = extent of resection; FLAIR = fluid-attenuated inversion recovery; FLIRT = FMRIB Linear Image Registration Tool; FMRIB = Oxford Centre for Functional MRI of the Brain; FOV = field of view; FSL = FMRIB Software Library; HR = hazard ratio; IDH-1 = isocitrate dehydrogenase-1; MGMT = O6-methylguanin-DNA-methyltransferase; diffusion tensor imaging; extent of resection; glioblastoma; oncology; p = isotropic component; prognosis; progression-free survival; q = anisotropic component; volumetric study

Mesh:

Substances:

Year:  2016        PMID: 27058207     DOI: 10.3171/2016.1.JNS152153

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  21 in total

1.  Global Effects of Focal Brain Tumors on Functional Complexity and Network Robustness: A Prospective Cohort Study.

Authors:  Michael G Hart; Rafael Romero-Garcia; Stephen J Price; John Suckling
Journal:  Neurosurgery       Date:  2019-06-01       Impact factor: 4.654

2.  Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection.

Authors:  Matthias Schneider; Anna-Laura Potthoff; Vera C Keil; Ági Güresir; Johannes Weller; Valeri Borger; Motaz Hamed; Andreas Waha; Hartmut Vatter; Erdem Güresir; Ulrich Herrlinger; Patrick Schuss
Journal:  J Neurooncol       Date:  2019-09-04       Impact factor: 4.130

3.  Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.

Authors:  Jaume Capellades; Josep Puig; Sira Domenech; Teresa Pujol; Laura Oleaga; Angels Camins; Carles Majós; Rocio Diaz; Christian de Quintana; Pilar Teixidor; Gerard Conesa; Gerard Plans; Josep Gonzalez; Natalia García-Balañà; Jose Maria Velarde; Carmen Balaña
Journal:  J Neurooncol       Date:  2017-12-28       Impact factor: 4.130

Review 4.  Current Clinical Brain Tumor Imaging.

Authors:  Javier E Villanueva-Meyer; Marc C Mabray; Soonmee Cha
Journal:  Neurosurgery       Date:  2017-09-01       Impact factor: 4.654

5.  Supratotal resection in glioma: a systematic review.

Authors:  Charles N de Leeuw; Michael A Vogelbaum
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

Review 6.  Supramarginal Resection for Glioblastoma: It Is Time to Set Boundaries! A Critical Review on a Hot Topic.

Authors:  Francesco Guerrini; Elena Roca; Giannantonio Spena
Journal:  Brain Sci       Date:  2022-05-16

Review 7.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

8.  Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.

Authors:  Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2021-03-12

9.  Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center.

Authors:  Amer Haj; Christian Doenitz; Karl-Michael Schebesch; Denise Ehrensberger; Peter Hau; Kurt Putnik; Markus J Riemenschneider; Christina Wendl; Michael Gerken; Tobias Pukrop; Alexander Brawanski; Martin A Proescholdt
Journal:  Brain Sci       Date:  2017-12-25

10.  Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom.

Authors:  Ruichong Ma; Aswin Chari; Paul M Brennan; Andrew Alalade; Ian Anderson; Anna Solth; Hani J Marcus; Colin Watts
Journal:  Neurooncol Pract       Date:  2017-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.